Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death

References

• Broderick SR. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):215–220.
   PubMed Web of Science ®Google Scholar
• Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640.
   PubMed Web of Science ®Google Scholar
• Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: immunotherapy. Clin Chest Med. 2020;41(2):237–247.
   PubMed Web of Science ®Google Scholar
• Chiu YH, Hsu SH, Hsu HW, et al. Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. Int J Oncol. 2018;53(5):1967–1979.
   PubMed Web of Science ®Google Scholar
• Xing Y, Liu Y, Liu T, et al. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway. Cell Commun Signal. 2018;16(1):43.
   PubMedGoogle Scholar
• Jeong Y, Hellyer JA, Stehr H, et al. Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer. Clin Cancer Res. 2020;26(1):274–281.
   PubMed Web of Science ®Google Scholar
• Xu P, Jiang L, Yang Y, et al. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation. Theranostics. 2020;10(8):3767–3778.
   PubMed Web of Science ®Google Scholar
• Ma Z, Cai H, Zhang Y, et al. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1. Biochem Biophys Res Commun. 2017;490(2):309–316.
   PubMed Web of Science ®Google Scholar
• Yu S, Ao Z, Wu Y, et al. ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer. Cell Prolif. 2020;53(11):e12924.
   PubMed Web of Science ®Google Scholar
• Tang D, Zhao D, Wu Y, et al. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med. 2018;22(8):3847–3856.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Fujita Y, Hosaka Y, et al. Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer. Cancer Sci. 2020;111(11):4154–4165.
   PubMed Web of Science ®Google Scholar
• Hu C, Zhang M, Moses N, et al. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53. Cell Death Dis. 2020;11(5):328.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao M, Cui L, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020;19(1):134.
   PubMed Web of Science ®Google Scholar
• Wu H, Mu X, Liu L, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020;11(9):801.
   PubMed Web of Science ®Google Scholar
• Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39(1):149.
   PubMed Web of Science ®Google Scholar
• Zamagni A, Pasini A, Pirini F, et al. CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells. Int J Oncol. 2020;56(6):1574–1584.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu Q, Lu L, et al. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1. Bioengineered. 2020;11(1):91–102.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhou X, Chen Y, et al. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs). Neoplasma. 2020;67(1):147–157.
   PubMed Web of Science ®Google Scholar
• Yang W, Xiao W, Cai Z, et al. miR-1269b drives cisplatin resistance of human non-small cell lung cancer via modulating the PTEN/PI3K/AKT signaling pathway. Onco Targets Ther. 2020;13:109–118.
   PubMed Web of Science ®Google Scholar
• Sun B, Hu N, Cong D, et al. MicroRNA-25-3p promotes cisplatin resistance in non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route. Bioengineered. 2021;12(1):3219–3228.
   PubMed Web of Science ®Google Scholar
• Wei L, Jiang J. Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment. Bioengineered. 2021;12(1):2499–2510.
   PubMed Web of Science ®Google Scholar
• Zhao W, Cao L, Zeng S, et al. Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression. Biomed Pharmacother. 2015;75:142–147.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu X, Lan J, et al. Circular RNA circRPPH1 promotes triple-negative breast cancer progression via the miR-556-5p/YAP1 axis. Am J Transl Res. 2020;12(10):6220–6234.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu R, Li Q, et al. SNHG1/miR-556-5p/TCF12 feedback loop enhances the tumorigenesis of meningioma through Wnt signaling pathway. J Cell Biochem. 2020;121(2):1880–1889.
   PubMed Web of Science ®Google Scholar
• Moro M, Caiola E, Ganzinelli M, et al. Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018;13(11):1692–1704.
   PubMed Web of Science ®Google Scholar
• Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, et al. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition. Free Radic Biol Med. 2019;135:167–181.
   PubMed Web of Science ®Google Scholar
• Ma Y, Yuwen D, Chen J, et al. Exosomal transfer of cisplatin-induced miR-425-3p confers cisplatin resistance in NSCLC through activating autophagy. Int J Nanomedicine. 2019;14:8121–8132.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hao F, Nan Y, et al. PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis. Int J Biol Sci. 2018;14(13):1883–1891.
   PubMed Web of Science ®Google Scholar
• Liu L, Fan J, Ai G, et al. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 2019;52(1):37.
   PubMedGoogle Scholar
• Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sui S, Wang L, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020;235(4):3425–3437.
   PubMed Web of Science ®Google Scholar
• Peng Z, Wang P, Song W, et al. GSDME enhances Cisplatin sensitivity to regress non-small cell lung carcinoma by mediating pyroptosis to trigger antitumor immunocyte infiltration. Signal Transduct Target Ther. 2020;5(1):159.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhou X, Chen Z, et al. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging (Albany NY). 2020;12(6):4711–4726.
   PubMedGoogle Scholar
• Long K, Gu L, Li L, et al. Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer. Cell Death Dis. 2021;12(6):503.
   PubMed Web of Science ®Google Scholar
• He B, Shi Y, Liang Y, et al. Single-walled carbon-nanohorns improve biocompatibility over nanotubes by triggering less protein-initiated pyroptosis and apoptosis in macrophages. Nat Commun. 2018;9(1):2393.
   PubMedGoogle Scholar
• Pi S, Nie G, Wei Z, et al. Inhibition of ROS/NLRP3/Caspase-1 mediated pyroptosis alleviates excess molybdenum-induced apoptosis in duck renal tubular epithelial cells. Ecotoxicol Environ Saf. 2021;208:111528.
   PubMed Web of Science ®Google Scholar
• Shi T, Fujita K, Gong J, et al. Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. Oncol Rep. 2020;44(2):457–468.
   PubMed Web of Science ®Google Scholar
• Wen Z, Mai Z, Zhu X, et al. Mesenchymal stem cell-derived exosomes ameliorate cardiomyocyte apoptosis in hypoxic conditions through microRNA144 by targeting the PTEN/AKT pathway. Stem Cell Res Ther. 2020;11(1):36.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu X, Bai X, et al. Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. J Pineal Res. 2018;64(2):e12449.
   Web of Science ®Google Scholar
• Mao Q, Liang XL, Zhang CL, et al. LncRNA KLF3-AS1 in human mesenchymal stem cell-derived exosomes ameliorates pyroptosis of cardiomyocytes and myocardial infarction through miR-138-5p/Sirt1 axis. Stem Cell Res Ther. 2019;10(1):393.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gao P, Wang Z, et al. Circ-LAMP1 contributes to the growth and metastasis of cholangiocarcinoma via miR-556-5p and miR-567 mediated YY1 activation. J Cell Mol Med. 2021;25(7):3226–3238.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang M, Zhao H, et al. Targeting a novel hsa_circ_0000520/miR-556-5p/NLRP3 pathway-mediated cell pyroptosis and inflammation attenuates ovalbumin (OVA)-induced allergic rhinitis (AR) in mice models. Inflamm Res. 2021;70(6):719–729.
   Web of Science ®Google Scholar
• Zhu X, Han J, Lan H, et al. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC). BMC Cancer. 2020;20(1):1190.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang S, Guo L, et al. Fixed differences in the 3ʹUTR of buffalo PRNP gene provide binding sites for miRNAs post-transcriptional regulation. Oncotarget. 2017;8(28):46006–46019.
   PubMedGoogle Scholar
• Hou Z, Wang Y, Xia N, et al. Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR. Cancer Sci. 2021;112(1):275–286.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang P, Li HX. CAFs-derived exosomal miRNA-130a confers cisplatin resistance of NSCLC cells through PUM2-dependent packaging. Int J Nanomedicine. 2021;16:561–577.
   PubMed Web of Science ®Google Scholar